Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Timing of Hepatitis B Vaccination After HCT
NCT06888479Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (4 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Titer of hepatitis B surface antibodies. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT06888479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888479.